Landiolol hydrochloride for prevention of postoperative atrial fibrillation after esophageal cancer surgery: The double-blind, randomized, placebo-controlled trial

Trial Profile

Landiolol hydrochloride for prevention of postoperative atrial fibrillation after esophageal cancer surgery: The double-blind, randomized, placebo-controlled trial

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Landiolol (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms APPLE
  • Most Recent Events

    • 01 Jul 2017 Primary endpoint (Incidence of atrial fibrillation ) has been met, as per the results published in the British Journal of Surgery.
    • 01 Jul 2017 Results published in the British Journal of Surgery
    • 01 Jul 2017 Status changed from active, no longer recruiting to completed, as per results published in the British Journal of Surgery.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top